Esquenazi A - Search Results

1

Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity.

Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A. Jacinto J, et al. Among authors: esquenazi a. Front Neurol. 2020 May 7;11:388. doi: 10.3389/fneur.2020.00388. eCollection 2020. Front Neurol. 2020. PMID: 32477251 Free PMC article.

2

Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity.

Esquenazi A. Esquenazi A. Eur J Neurol. 2006 Dec;13 Suppl 4:27-34. doi: 10.1111/j.1468-1331.2006.01651.x. Eur J Neurol. 2006. PMID: 17112347 Review.

3

Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies.

Esquenazi A, Delgado MR, Hauser RA, Picaut P, Foster K, Lysandropoulos A, Gracies JM. Esquenazi A, et al. Front Neurol. 2020 Sep 25;11:576117. doi: 10.3389/fneur.2020.576117. eCollection 2020. Front Neurol. 2020. PMID: 33101184 Free PMC article.

4

Corrigendum: Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity.

Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A. Jacinto J, et al. Among authors: esquenazi a. Front Neurol. 2020 Dec 17;11:629181. doi: 10.3389/fneur.2020.629181. eCollection 2020. Front Neurol. 2020. PMID: 33391178 Free PMC article.

5

Corrections required for Dressler and Johnson 2022.

Esquenazi A, Elliott M, Lysandropoulos A. Esquenazi A, et al. J Neural Transm (Vienna). 2022 Oct;129(10):1307-1308. doi: 10.1007/s00702-022-02534-0. Epub 2022 Aug 30. J Neural Transm (Vienna). 2022. PMID: 36040626 Free PMC article. No abstract available.

6

Botulinum neurotoxin in muscle overactivity.

Esquenazi A. Esquenazi A. J Head Trauma Rehabil. 2005 Nov-Dec;20(6):563-7. doi: 10.1097/00001199-200511000-00007. J Head Trauma Rehabil. 2005. PMID: 16304491 Review. No abstract available.

7

International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments--introduction.

Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. Esquenazi A, et al. Eur J Neurol. 2010 Aug;17 Suppl 2:1-8. doi: 10.1111/j.1468-1331.2010.03125.x. Eur J Neurol. 2010. PMID: 20633176 Review.

8

Patient registry of outcomes in spasticity care.

Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S; PROS Study Group. Esquenazi A, et al. Am J Phys Med Rehabil. 2012 Sep;91(9):729-46. doi: 10.1097/PHM.0b013e31824fa9ca. Am J Phys Med Rehabil. 2012. PMID: 22469872

9

Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.

Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, Smith CP, Ward AB. Esquenazi A, et al. Toxicon. 2013 Jun 1;67:115-28. doi: 10.1016/j.toxicon.2012.11.025. Epub 2012 Dec 5. Toxicon. 2013. PMID: 23220492 Review.

10

Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial.

Esquenazi A, Stoquart G, Hedera P, Jacinto LJ, Dimanico U, Constant-Boyer F, Brashear A, Grandoulier AS, Vilain C, Picaut P, Gracies JM. Esquenazi A, et al. PM R. 2020 Sep;12(9):853-860. doi: 10.1002/pmrj.12348. Epub 2020 Mar 27. PM R. 2020. PMID: 32108436 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127 results

Search Page